Appointment of Chairman of the Board

RNS Number : 2161R

MaxCyte, Inc.

03 November 2021

 

MaxCyte Board Member Richard Douglas, PhD, Appointed Independent Chairman of the Board

GAITHERSBURG, MD, Nov. 3, 2021 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. The company today announces that its Board of Directors has appointed Richard Douglas, PhD, as Chair of the Board.  Richard Douglas has been a Non-Executive Director since February 2018.  He succeeds J. Stark Thompson, PhD, who previously announced his decision not to seek re-election. Dr. Thompson will remain as a consultant to MaxCyte.

"MaxCyte's ExPERT^TM technology and cell engineering expertise is well-known throughout the industry and I'm extremely proud to step into the role of Board Chair on the heels of its first U.S. public offering, which marks a pivotal time in the Company's history," said Dr. Douglas.

Dr. Douglas is a veteran pharmaceutical executive who presently serves as an adviser at RedSky Partners, Chair of the Board of Aldeyra Therapeutics, a director of Novavax Inc., and Chair of the National Advisory Board of Innovation Partnerships at the University of Michigan. He formerly held the role of Senior Vice President of Corporate Development and Corporate Officer at Genzyme Corporation where he led numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. He had previously held scientific and corporate development roles at Integrated Genetics.

"Since bringing his wealth of experience to the board in 2018, Richard has been a valuable contributor as we sought to list on the Nasdaq. His new role is a natural transition for him to continue the strong, impactful leadership that MaxCyte has enjoyed under Stark's guidance of the Board since the founding of MaxCyte," commented Doug Doerfler, Chief Executive Officer, President and Founder of MaxCyte. "Stark helped set the foundation as we built MaxCyte to be the leading enabling platform technology in cell therapy worldwide.  It has been a true honor to work with him and we thank him for his dedication and perspective."

"It has been an honor to serve on the MaxCyte board.  The company is well positioned to continue providing its industry-leading technology to the rapidly expanding cell therapy development pipeline," remarked Dr. Thompson.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation^® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	[phone]   [e-mail]
US Media Relations Laura Morgan Sam Brown Healthcare Communications	[phone] [e-mail]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

 

END

 

 

BOABJBMTMTTMBJB